Home › Research › Prevention and risk
Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan
Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, Lu RB, Chang HA et al.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018-04-01
Topic: Risk, prevention and care in population studies
Plain-language summary
This retrospective cohort study is to investigate the association between herpes simplex virus (HSV) infections and dementia, and the effects of anti-herpetic medications on the risk involved, using Taiwan's National Health Insurance Research Database (NHIRD). We enrolled a total of 33,448 subjects, and identified 8362 with newly diagnosed HSV infections and 25,086 randomly selected sex- and age-matched controls without HSV infections in a ratio of 1:3, selected from January 1, to December 31, 2000. A multivariable Cox proportional hazards regression model was used to evaluate the risk of developing dementia in the HSV cohort. This analysis revealed an adjusted hazard ratio of 2.564 (95% CI: 2.351-2.795, P < 0.001) for the development of dementia in the HSV-infected cohort relative to the non-HSV cohort. Thus, patients with HSV infections may have a 2.56-fold increased risk of developing dementia. A risk reduction of dementia development in patients affected by HSV infections was found upon treatment with anti-herpetic medications (adjusted HR = 0.092 [95% CI 0.079-0.108], P < 0.001). The usage of anti-herpetic medications in the treatment of HSV infections was associated with a decreased risk of dementia. These findings could be a signal to clinicians caring for patients with HSV infections. Further research is, therefore, necessary to explore the underlying mechanism(s) of these associations.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 33,448 participants. In this cohort, patients with herpes simplex virus infections had a 2.56-fold increased risk of developing dementia compared with those without. Reported effect size: HR = 0.092.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tzeng, N. S., Chung, C. H., Lin, F. H., Chiang, C. P., Yeh, C. B., Huang, S. Y., et al. (2018). Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. https://doi.org/10.1007/s13311-018-0611-x
Vancouver
Tzeng NS, Chung CH, Lin FH, Chiang CP, Yeh CB, Huang SY, et al. Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018. doi:10.1007/s13311-018-0611-x. PMID: 29488144.
BibTeX
@article{tzeng2018-29488144,
author = {Tzeng, N. S. and Chung, C. H. and Lin, F. H. and Chiang, C. P. and Yeh, C. B. and Huang, S. Y. and Lu, R. B. and Chang, H. A. and others},
title = {{Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan}},
journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
year = {2018},
doi = {10.1007/s13311-018-0611-x},
pmid = {29488144},
url = {https://doi.org/10.1007/s13311-018-0611-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This analysis revealed an adjusted hazard ratio of 2.564 (95% CI: 2.351-2.795, P < 0.001) for the development of dementia in the HSV-infected cohort relative to the non-HSV cohort.
- Thus, patients with HSV infections may have a 2.56-fold increased risk of developing dementia.
- The usage of anti-herpetic medications in the treatment of HSV infections was associated with a decreased risk of dementia.
- These findings could be a signal to clinicians caring for patients with HSV infections.
Why it matters
In this cohort, patients with herpes simplex virus infections had a 2.56-fold increased risk of developing dementia compared with those without. Treatment with anti-herpetic medications was associated with a decreased risk of dementia, which the authors say could be a signal to clinicians but requires further research into the mechanism.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort study
- Participants33,448
- Effect sizeHR = 0.092
- Evidence strengthModerate
How this study scored 68/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics) |
| Journal's citation record | 2 / 4 | Neurotherapeutics: journal h-index 156 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 4 / 4 | 33,448 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 354 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 35.4 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 5 / 6 | Cited 26.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 3 / 4 | Cited 109 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Wu‐Chien Chien: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | National Cheng Kung University: institution h-index 481 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29488144) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s13311-018-0611-x
- PubMed: 29488144
- Original source →
- Free full text: Neurotherapeutics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also tagged “chronic-infection-and-cognitive-decline”
3 studies in the library carry the topic tag “chronic-infection-and-cognitive-decline”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.